Crinetics Pharmaceuticals (CRNX) Assets

Price: $32.39
Market Cap: $3.01B
Avg Volume: 1.01M
Country: US
Industry: Biotechnology
Sector: Healthcare
Beta: 0.375
52W Range: $24.1-62.53
Website: Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Asset Metrics Summary

According to Crinetics Pharmaceuticals's latest annual financial reports, the company's asset profile is as follows:

Total Assets

Crinetics Pharmaceuticals's total assets amount to $1.43B. This is divided into:

  • Total Current Assets: $1.38B
  • Total Non-current Assets: $59.20M
  • Net Receivables: $-
  • Inventory: $-
  • Cash and Short-term Investments: $1.35B
  • Property, Plant, and Equipment (Net): $55.58M
  • Long-term Investments: $-
  • Goodwill and Intangible Assets: $-

Asset Ratios and Metrics

To better understand Crinetics Pharmaceuticals's asset management, we can look at several key ratios:

  • Return on Assets (ROA): -20.80% - this indicates how profitable a company is relative to its total assets.
  • Asset Turnover: 0.00 - this shows how efficiently a company uses its assets to generate sales.
  • Current Ratio: 23.04 - this measures a company's ability to pay short-term obligations with its current assets.
  • Quick Ratio: 23.04 - this indicates a company's ability to meet short-term obligations with its most liquid assets.
  • Cash Ratio: 4.43 - this measures a company's ability to pay off short-term liabilities with its cash and cash equivalents.

These metrics provide insight into Crinetics Pharmaceuticals's asset efficiency and liquidity. For a comprehensive understanding of the company's financial health, it's important to consider these asset metrics alongside other financial indicators and industry benchmarks.

Total Assets

$1.43B

Total Current Assets

$1.38B

Total Non-current Assets

$59.20M

Net Receivables

$-

Inventory

$-

Cash and Short-term Investments

$1.35B

Property, Plant, and Equipment (Net)

$55.58M

Long-term Investments

$-

Goodwill and Intangible Assets

$-

Return on Assets

-20.80%

Asset Turnover

0.00

Current Ratio

23.04

Crinetics Pharmaceuticals Historical Asset Metrics
Total Assets
Total Current Assets
Total Non-current Assets
$1.60B$1.60B$1.20B$1.20B$800.00M$800.00M$400.00M$400.00M$0.00$0.00Asset Metrics2017201720182018201920192020202020212021202220222023202320242024
Historical Return on Assets
11.74%11.74%-0.00%-0.00%-11.74%-11.74%-23.48%-23.48%-35.22%-35.22%-46.96%-46.96%-58.71%-58.71%Return on Assets201720172018201820192019202020202021202120222022202320232024202420252025
Historical Total Assets Growth
1200.00%1200.00%900.00%900.00%600.00%600.00%300.00%300.00%0.00%0.00%-300.00%-300.00%Total Assets Growth201720172018201820192019202020202021202120222022202320232024202420252025

Crinetics Pharmaceuticals Historical Assets

The table below shows various asset metrics for each year, with the latest data available for the last fiscal year 2024.

Year Total Assets Total Current Assets Total Non-current Assets Net Receivables Inventory Cash and Short-term Investments Property, Plant, Equipment (Net) Long-term Investments Goodwill and Intangible Assets Return on Assets Asset Turnover Current Ratio Quick Ratio Cash Ratio
2024 $1.43B $1.38B $59.20M $- $- $1.35B $55.58M $- $- -0.21 0.00 23.04 23.04 4.43
2023 $635.35M $574.15M $61.20M $9.35M $- $558.55M $57.43M $1.77M $- -0.34 0.01 13.07 13.07 1.25
2022 $352.18M $345.18M $6.99M $- $- $334.43M $4.99M $1.97M $- -0.45 0.01 12.45 12.45 1.18
2021 $351.01M $344.72M $6.29M $2.03M $8.07M $333.71M $4.72M $1.01M $- -0.30 0.00 21.55 21.05 12.55
2020 $183.44M $177.49M $5.95M $1.83M $-1.83M $170.88M $5.41M $500.00K $- -0.40 0.00 16.92 17.10 8.87
2019 $130.38M $123.34M $7.04M $- $-1.38M $118.39M $6.46M $500.00K $- -0.38 0.01 14.79 14.95 4.84
2018 $171.41M $166.68M $4.73M $- $- $163.88M $4.23M $500.00K $- -0.16 0.01 21.03 21.03 5.67
2017 $15.60M $15.16M $433.00K $734.00K $141.00K $14.19M $400.00K $- $- -0.59 0.13 16.91 16.75 15.82
2016 $12.60M $12.37M $234.00K $72.00K $98.00K $12.15M $224.00K $- $- -0.48 0.05 13.89 13.78 13.65

Related Metrics

Explore detailed financial metrics and analysis for CRNX.